In early February this year, a few days after a magnetic resonance image confirmed that an aneurysm at the root of my aorta had reached a worrisome size, I received a phone call from the office of my primary care physician. The MRI had picked up an “incidental” finding, unrelated to the aneurysm; could I come into the office to discuss it?
The incidental finding turned out to be a type of pancreatic cyst called, ominously, an intraductal papillary mucinous neoplasm (IPMN). It’s probably nothing to worry about, my doctor assured me, but it would be prudent to have a high-resolution MRI of the abdomen and the pancreas to get a better look at what we’re dealing with. The MRI confirmed that the cyst was an IPMN, about 2 centimeters (almost an inch) long. The recommendation: repeat the MRI in 3 months to make sure nothing has changed.
At that point, I was in full reporter mode, having just learned that my aortic aneurysm, which I had basically dismissed for 12 years, could no longer be ignored. I set out to learn all I could about IPMNs. It’s an interesting story that raises hopes of early detection of more cases of pancreatic cancer—one of the deadliest cancers—and some tricky questions about the benefits and costs of screening for these and similar lesions. It would be an even better story for me if I were not in the middle of it. Continue reading

lop ebola. In the days before he died, Duncan infected two nurses. Last month, a New York doctor who had been working with Doctors without Borders in Guinea was diagnosed with the disease, becoming the fourth person to develop the disease in the US. The case count is vanishingly small, yet the infections have sparked a highly contagious epidemic of fear and prompted some states to adopt draconian quarantine policies.



